Protein Research
Laboratory

Accepted date: Sep-05-2023 

Minjee Kim^¶, Hyeyoung Kim^¶, Bu-Gyeong Kang^¶, Jooyoung Lee^¶, Taegun Kim^¶, Hwanho Lee, Jane Jung, Myung Joon Oh, Seungyoon Seo, Myung-Jeom Ryu, Yeojin Sung, Yunji Lee, Jeonghun Yeom, Gyoonhee Han*, Sun-Shin Cha*, Hosung Jung*, Hyun Seok Kim*

"Discovery of a novel NAMPT inhibitor that selectively targets NAPRT-deficient EMT-subtype cancer cells and alleviates chemotherapy-induced peripheral neuropathy " Theranostics (2023)

Abstract of this paper:

Exploiting synthetic lethality (SL) relationships between protein pairs has emerged as an important avenue for the development of anti-cancer drugs. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme of the NAD+ salvage pathway, having an SL relationship with nicotinic acid phosphoribosyltransferase (NAPRT), the key enzyme in the NAD+ Preiss-Handler pathway. NAMPT inhibitor holds clinical potential not only as a promising cancer treatment but also as a means of protection against chemotherapy-induced-peripheral-neuropathy (CIPN). However, as NAD+ is essential for normal cells, the clinical use of NAMPT inhibitors is challenging. This study aimed to identify a novel NAMPT inhibitor with enhanced selective cytotoxicity against NAPRT-deficient cancer cells as well as prominent efficacy in alleviating CIPN.

본 연구는 연세대학교 김현석 교수님, 정호성 교수님, 한균희 교수님 연구실과의 공동연구를 통해 이루어졌습니다.